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Sex Med 2Background: Patients with sleep-related painful erections (SRPEs) have deep penile pain during nocturnal
erection that wakes them up and disturbs their nights of sleep. This rare parasomnia is poorly recognized by
general practitioners and by urologists and sexologists.
Aim: To gain more insight into diagnostics and therapeutic options.
Methods: Data from a series of 24 consecutive patients who presented with SRPEs at the outpatient clinic from
1996 to 2015 were retrospectively analyzed. Additional questionnaires were completed to complement data and
to obtain information about follow-up. Long-term treatment efﬁcacy of baclofen was assessed using the
Wilcoxon signed rank test.
Outcomes: SRPEs were not associated with urologic, surgical, or psychiatric history or with serum testosterone
levels. The mean doctors’ delay was 3.5 years. 14 of the 24 patients were treated with baclofen (10e75 mg). In
11 of them, complete remission was observed within a few weeks. 2 of the 3 remaining patients noticed a slight
improvement of SPRE symptoms and only 1 patient experienced no effect at all. After an average follow-up of
4.5 years, only 41.6% of patients who had used baclofen were satisﬁed with their SRPEs. The others (58.4%)
were dissatisﬁed, mostly owing to relapse of symptoms after the discontinuation of baclofen. Other treatment
forms were applied sporadically, with strongly varying results.
Clinical Implications: This overview of SRPE contributes to a better clinical understanding and recognition of
the phenomenon and provides new, more constructed advice about therapeutic implications, especially con-
cerning the use of baclofen.
Strengths and Limitations: This study provides a systematic overview of a relatively large series of patients
with SRPE, which provides substantiated treatment advice. However, treatment efﬁcacy was based mainly on the
patients’ subjective perception and it was not possible to compare the results of baclofen with other forms of
pharmacologic treatment, because these alternative drugs were applied only sporadically. Nevertheless, this study
is directional for future research.
Conclusions: This study conﬁrmed a long doctors’ delay in patients with SRPE. There was no association
between SRPEs and comorbidity and total serum testosterone levels. Treatment with baclofen proved successful
and safe in the short term. Long-term feasibility needs further investigation. Vreugdenhil S, Weidenaar AC, de
Jong IJ, van Driel MF. Sleep-Related Painful Erections—A Case Series of 24 Patients Regarding
Diagnostics and Treatment Options. Sex Med 2017;5:e237ee243.
Copyright  2017, The Authors. Published by Elsevier Inc. on behalf of the International Society for Sexual Medicine.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Patients with sleep-related painful erections (SRPEs) experi-
ence episodes of penile pain during nocturnal erections that
frequently wake them up. SRPEs occur during rapid eye move-
ment (REM) sleep. However, erections related to sexual activities
are not painful and are normal in duration and rigidity and
generally no penile anatomic abnormalities are found duringe237
e238 Vreugdenhil et alphysical examination. Obviously, Peyronie’s disease and phi-
mosis can be present in some patients but they seldom explain
the typical clinical presentation of SRPEs.1
The intensity of pain and duration of the associated sleep
deﬁcit commonly increase during the second part of the night
when REM sleep episodes become longer and more frequent.2
The underlying pathophysiologic mechanism and predisposing
factors for SRPEs are not known. Treatment is still in an expert-
based opinion phase and there is no consensus about how to treat
this parasomnia. In addition, there is a lack of information about
long-term follow-up. By documenting the symptomatology,
diagnostic measurements, and treatment outcomes of our pa-
tients with SRPE, we aimed to gain a better understanding of the
pathophysiology and to develop more substantiated advice about
the diagnostics and therapeutic implications of SRPEs.METHODS
Study Population
In this retrospective descriptive study, we collected data from
all patients who presented with SRPE complaints at our outpa-
tient clinic from 1996 to July 2015. 2 patients included in this
study were previously described.2 Patients who also had painful
erotic erections or anatomic abnormalities (eg, Peyronie’s disease
and phimosis) were excluded. 2 patients who developed Peyro-
nie’s disease a couple of years after the onset of SRPE and pa-
tients with daytime painful non-erotic erections during follow-up
were included. Information about demographics, symptom-
atology, psychosocial factors, ﬁndings at physical examination,
and diagnostics were extracted from the patients’ medical ﬁles.
Special attention was paid to the applied treatment modalities,
their effectiveness, and their adverse event proﬁle. Questionnaires
(Appendix) about the subjective perception of short- and long-
term results were sent to all patients. Classiﬁcation of treat-
ments was based on their answers (0 ¼ no effect, 1 ¼ partial
remission, 2 ¼ full remission). Satisfaction concerning the ach-
ieved effect was classiﬁed into 3 categories (0 ¼ dissatisﬁed, 1 ¼
moderately satisﬁed, 2 ¼ satisﬁed).Analysis
Data were analyzed using IBM SPSS Statistics Data Editor 23
(IBM Corp, Armonk, NY, USA). The primary end points of
treatment efﬁcacy in the short term (ﬁrst 3 months of treatment)
were change in frequency and duration of SRPEs as reported by
the patient. Frequency was divided into 6 categories (0 ¼ no
SRPE, 1 ¼ 0e1 time per night, 2 ¼ 1e2 times per night, 3 ¼
2e3 times per night, 4 ¼ 3e4 times per night, 5 ¼ 4e5 times
per night, 6 ¼ >5 times per night). Duration was classiﬁed into
5 categories (0 ¼ no SRPE, 1 ¼ 1e15 minutes, 2 ¼ 16e30
minutes, 3 ¼ 31e60 minutes, 4 ¼ >61 minutes). Differences in
the average frequency and duration of SRPEs of patients treated
with baclofen before vs (years) after treatment were estimated
using the Wilcoxon signed rank test. All tests were 2-tailed and asigniﬁcant difference was deﬁned as a P value less than or equal
to .05. Effect size was interpreted according to Cohen. The
baclofen group alone was large enough to be assessed in this
manner. Participants who quit treatment prematurely because of
side effects or for other reasons contributed to the average out-
comes. Data of patients who did not return the questionnaire
were disregarded for follow-up analysis.RESULTS
Demographics
We included 24 patients with a median age of 53 years
(range ¼ 38e74) at the onset of SRPEs. 22 completed the
questionnaires. All men were heterosexual and most were mar-
ried for a longer period. 2 were in a divorce during the onset of
SRPEs, 2 were single, and 1 had recently become a widower.
Table 1 presents the medical or psychiatric history including
urogenital, abdominal or spine surgery, chronic and psychiatric
disease, and urologic illness.Symptomatology
The median time from the onset of SRPEs to the ﬁrst
consultation with a urologist was 2.5 years (range ¼ 0.5e20).
The median frequency of nocturnal awakenings as result of a
painful erection was 3 times a night (range ¼ 1e10), and the
erection persisted shorter than 15 minutes in 45% of patients. In
37% the duration was shorter than 60 minutes and in 4 (18%)
the SRPEs persisted up to 1 hour. The pain was often described
as stabbing, aching, and/or pressing. 12 of the 24 patients re-
ported radiation to at least 1 adjacent area (Table 2).
After waking up from an SRPE, several maneuvers were
applied to achieve detumescence (Figure 1). Urinating and
walking around proved to be the most effective, respectively, in
54% and 50% of the 22 patients. There were different experi-
ences concerning the effect of alcohol and eating before bedtime.
However, all men reported that staying in bed maintained or
even worsened the erection. 1 patient explicitly mentioned that
marital issues and related stress were strongly inﬂuencing his
complaints. After the divorce, he said, his SRPEs had disappeared
spontaneously. Another patient noticed a relation between stress
levels from his work and the severity of his complaints.
More than 80% reported sexual satisfaction to be unchanged
since start of the symptoms. SRPEs appeared not to impair
erectile function. However, sex drive decreased in 8 of the 24
men (33%). All patients complained about sleep deprivation and
for nearly all of them this was the main reason why they had
consulted a physician. Daytime sleepiness and fatigue were re-
ported by 78.8%. In 25% (n ¼ 6) daytime fatigue had forced
them to partial or complete work absenteeism.Diagnostics
In 22 of the 24 patients, serum testosterone levels were
measured in the morning from 9 to 10 AM. The mean serumSex Med 2017;5:e237ee243



















11* x x x
12† x x
Total 7 2 4 4 2
*Patient also experienced painful non-erection erections during daytime.
†Patient also experienced lower urinary tract symptoms.
Table 1. Patient characteristics: overview of medical history with

































Urogenital 3 Scrotal surgery 2,
TUR of prostate 1













Varicocele 1 Surgery needed
Post-vasectomy
syndrome




Mood disorder 2 Depression 2, with
anxiety disorder in 1
COPD ¼ chronic obstructive pulmonary disease; CPAP ¼ continuous pos-
itive airway pressure; LUTS ¼ lower urinary tract symptoms; OSAS ¼



































Figure 1. Maneuvers performed by patients to achieve
detumescence.
Sleep-Related Painful Erections e239testosterone level was 16.4 nmol/L (SD ¼ 5.07). 6 had a level
below 14 nmol/L. The patient with a level of 5.6 nmol/L had a
history of prolactinoma. None of the patients had a testosterone
level above the upper limit.Sex Med 2017;5:e237ee243To visualize the duration and intensity of the SRPEs, 15 of 24
patients underwent nocturnal penile tumescence and rigidity
(NPT-R) measurements. In 2 patients NPT-R was combined
with polysomnography (PSG). According to the age-related
criteria formulated by Burris et al,3 NPT-R measurements
were aberrant in 7 of these 15 patients and showed prolonged
episodes with erection. One patient could not ﬁnish the NPT-R
measurement because of pain and the other 7 showed a normal
pattern. 1 of the 2 patients in whom PSG was performed showed
typical characteristics: an increased percentage of REM sleep
(25%) and all REM episodes accompanied by erection and
subsequent awakening, resulting in sleep fragmentation and
decreased sleep efﬁciency of 73%. Simultaneously performed
electromyography of the pelvic ﬂoor muscles showed irregular
increase of muscle tonus during REM sleep episodes. In the other
patient, PSG showed no abnormalities.
In 8 men Doppler ultrasound of the cavernosal arteries
showed an increased rest ﬂow in 3 (0.26, 0.28, and 0.37 m/s,
respectively). The others showed normal values.
Table 3. Treatment: overview applied treatment per patient with short- and long-term results and reported side effects
Age (years) Treatment Result (short term)* Side effects
41 Baclofen 20 mg 1 None
44 Baclofen 10 mg 2 None
55 Baclofen 30 mg 1 Weight gain
66 Baclofen 20 mg 1 Debilitating headache
69 Baclofen 30 mg 1 None
53 Baclofen 10 mg þ cyproterone acetate 50 mg 1 Loss of sex drive
71 Baclofen 20 mg þ cyproterone acetate 50 mg 2 None
58 Baclofen 75 mg 2 None
Cyproterone acetate 20 mg 0 Loss of sex drive, erectile dysfunction
40 Baclofen 20e30 mg 1 Myalgia with 30 mg, none with 20 mg
Cyproterone acetate 50 mg 0 None
Amitriptyline 0 Delusions, suicidal thoughts
Pelvic physiotherapy 0 None
43 Baclofen 30 mg 0 Mild drowsiness
Cyproterone acetate 10 mgþ amitriptyline 20 mg 0 Loss of sex drive, erectile dysfunction
Cyproterone acetate 30 mg 0 Itching around genitals
47 Baclofen 30 mg 2 None
Cyproterone acetate 10 mg 0 Fever?
Amitriptyline 1 Drowsiness, mood swings
Carbamazepine 0 None
Pelvic physiotherapy 0 Nine
62 Baclofen 80 mg 1 None
Cyproterone acetate 50 mg 0 None
Amitriptyline 30 mg 1 None
Tadalaﬁl 5 mg 0 More erections
53 Baclofen 30 mg 1 Mild fatigue and lethargy (in morning)
Carbamazepine 100 mg 1 None
53 Tadalaﬁl 5 mg ? None
Baclofen 10 mg 2 Mild headache (sometimes)
47 Amitriptyline 0 None
Pelvic physiotherapy 2 None
65 Tadalaﬁl 5 mg þ pelvic physiotherapy 2 None
58 Tadalaﬁl 5 mg 2 None
47 Sexologist 1 None
49 Sexologist þ venlafaxine 1 None
74 Sexologist þ pelvic physiotherapy 2 None
38 — 0 —
41 — 1 —
50 — 2 —
55 — 0 —
— ¼ no treatment.
*0 ¼ unaltered; 1 ¼ partial remission; 2 ¼ full remission.
e240 Vreugdenhil et alTreatment and Follow-Up
Before the initial visit to our outpatient clinic, different drugs
had been tried by patients prescribed by several specialists,
including benzodiazepines (clonazepam, nitrazepam, and oxaz-
epam), opiates (tramadol and OxyContin), antiepileptics (car-
bamazepine and pregabalin), antidepressants (mirtazapine,
paroxetine, venlafaxine, and amitriptyline), antihypertensives
(b-blockers and clonidine), and b-agonists (terbutaline). Except
for amitriptyline, none of these medications was effective
(enough) and/or had caused too many disabling side effects.After the ﬁrst consultation at our clinic, 4 of the 24 patients
refrained from further treatment. After extensive counseling on the
off-label use, 18 of the remaining 20 patients were willing to try a
pharmacologic treatment, with or without non-pharmacologic
interventions such as pelvic physiotherapy and/or sexological
counseling. 2 patients received only non-pharmacologic treatment.
Table 3 presents data on the applied treatment per patient, its
short-term effect, and reported side effects. In 22 of 24 patients,
data were available on the long-term results of the treatment after a






































































Figure 2. Long-term treatment results of baclofen. Median and
interquartile range of SRPE frequency and duration before treat-
ment compared with SRPE frequency and duration after long-term
follow-up in patients treated with baclofen. SRPE ¼ sleep-related
painful erection.
Sleep-Related Painful Erections e241Baclofen
Of the 18 patients receiving pharmacologic treatment, 14 were
treated with baclofen (Lioresal; Medtronic, Fridley, MN, USA)
starting with a dose of 10 mg at bedtime. Depending on the
(side) effects, the patient was advised to increment the dose,
initially up to a maximum of 40 mg. However, 2 men required a
dosage of 75 and 80 mg, respectively, before adequate
improvement was noticed. 5 of the 14 patients treated with
baclofen (35.7%) experienced complete remission of symptoms
after a few weeks, 8 (57.1%) noticed partial improvement, and
baclofen in 1 (7.1%) was not effective at all. In general, baclofen
was well tolerated. 2 patients used baclofen combined with
cyproterone acetate (50 mg).
Long-term information was available for 12 of the 14 patients.
We looked at the results of baclofen on frequency and duration
of SRPEs after a mean follow-up of 4.5 years (SD ¼ 3.25;
Figure 2). The Wilcoxon signed rank test showed a statistically
signiﬁcant decrease of mean SRPE frequency in the entire series
of patients treated with baclofen (P ¼ .026), with a medium
effect size (Z ¼ 2.232, r ¼ 0.43). The same was assessed for
SRPE duration. The mean SRPE duration the entire series of
patients using baclofen had decreased signiﬁcantly (P ¼ .038),
with a medium effect size (Z ¼ 2.070, r ¼ 0.43).
4 patients (33.3%) were completely free of symptoms and 2
were still using baclofen. 2 (16.7%) experienced a partial
remission about which 1 was completely satisﬁed in contrast to
the other. In 6 patients (50%), SRPEs fully relapsed after
discontinuation of baclofen. Only 3 patients were successfullySex Med 2017;5:e237ee243using baclofen after 0.5, 4.5, and 1 years, respectively, in the
absence of any signiﬁcant side effects.Other Treatment Modalities
Other pharmacologic treatments included cyproterone acetate
(Androcur; Bayer LPC, Reading, UK), an antiandrogen; tadalaﬁl
(Cialis; Eli Lilly, Indianapolis, IN, USA), a phosphodiesterase
type 5 inhibitor; and amitriptyline (Sarotex; Saertex GmbH &
Co, Saerbeck, Germany), a tricyclic antidepressant.
Cyproterone acetate was used by 7 patients, dosages varied
from 10 to 50 mg, and the drug was efﬁcacious in only 1 patient
who used cyproterone acetate 50 mg combined with baclofen 20
mg. The remaining patients reported no relieving effect what-
soever. Moreover, the drug caused debilitating side effects,
including loss of sex drive and impaired sex-related erections.
Tadalaﬁl 5 mg once a day was used by 4 patients and 2 of
them experienced full remission (1 also had pelvic ﬂoor physi-
otherapy).This beneﬁcial effect in the short term was sustained in
the long term, but to a lesser extent after 5 years and 6 months,
respectively, of treatment. The other 2 patients experienced no
improvement or even aggravation of symptoms.
Amitriptyline was prescribed to 5 patients, of whom 1 used it
combined with cyproterone acetate and the other 4 used it as
monotherapy. 2 of these 5 reported partial remission, but the
other 3 (including the 1 patient using combination therapy)
experienced no remission whatsoever. Furthermore, 3 mentioned
disabling side effects including drowsiness and mood disorders.
5 patients were referred to a pelvic ﬂoor physiotherapist. In 2
of them, the therapy was combined with tadalaﬁl 5 mg or
sexological counseling. In the remaining 3, pelvic ﬂoor physio-
therapy was used as a last resort treatment option after several
previously disappointing experiences with drugs. 2 patients
experienced no remission of symptoms. The other 3 reported full
symptom remission in the short term; 1 received simultaneous
sexological counseling, 1 used tadalaﬁl at the same time, and 1
tried pelvic ﬂoor physiotherapy as monotherapy.
Of the 4 patients using no treatment in any form, 1 was
completely free of symptoms, 1 experienced partial remission, 1
had SRPEs without change, and in 1 data on this subject were
not available.
DISCUSSION
To our knowledge, this series is the largest study describing
patients with SRPEs with a relatively long follow-up. Data
showed heterogenicity for age of onset (38e74 years) and
medical background. In contrast, the symptomatology of SRPEs
appeared to be remarkably similar in all patients. For most pa-
tients, SRPEs did not negatively affect their sex life. However,
they caused signiﬁcant sleep deprivation and a vast majority of
patients (79%) had fatigue with considerable implications for
daily life. We found no association between SRPEs and
comorbidity.
e242 Vreugdenhil et alInitially almost all patients treated with baclofen (10e75 mg)
reported a substantial relief of symptoms. However, in the long
term only 41.6% of baclofen users were satisﬁed with the
treatment results, mostly because of relapse of symptoms after
discontinuation.
Other different drugs were used, with variable results. More
frequently used medicines, including amitriptyline (n ¼ 5) and
cyproterone acetate (n ¼ 7), were discontinued at an early stage
because of debilitating side effects. Moreover, in our patients,
cyproterone acetate had little or no effect on SRPEs. This is
remarkable because sleep-related erections depend more on
androgen than erections related to sexual activities.4e6 Other
pharmacologic treatment forms were used in only a small number
of patients, which makes it impossible to draw any conclusions.
Baclofen is a muscle relaxant with spinal and central points of
action. Rourke et al7 ﬁrst reported on the use of oral nightly
baclofen 40 mg in the management of recurrent priapism in
patients with neurologic lesions. At the spinal level, baclofen
inhibits mono- and polysynaptic reﬂex transmissions in the
afferent terminal nerves. Theoretically, the efﬁcacy of baclofen in
patients with SRPEs also could be based on relaxation of the
ischiocavernous, bulbospongiosus, and other pelvic ﬂoor mus-
cles. This probably proceeds through stimulation of g-amino-
butyric acid b-receptors, thus impeding the release of glutamic
and aspartic acid. Stimulation of the g-aminobutyric acid system
has an inhibitory effect on the frequency of nocturnal erec-
tions.8,9 Some of our observations suggest that SRPEs might be
related to hypertonia of the pelvic ﬂoor muscles. These include
the radiation of penile pain to adjacent areas, the high
concomitant occurrence of lower urinary tract symptoms, the
relation with psychological stress, and the alternating increased
pelvic ﬂoor muscle tone during REM sleep. In addition, we
found positive long-term treatment results of pelvic ﬂoor phys-
iotherapy in 3 of 5 patients.
There are some similarities between patients with SRPE and
those with so-called stuttering priapism (also known as inter-
mittent or recurrent priapism). The European guideline states
that the etiology of stuttering priapism is similar to that of
ischemic priapism, with sickle cell disease being the most
common cause.10 According to the UK guidelines, stuttering
priapism is often self-limiting or resolves after oral medication or
conservative therapeutic maneuvers that patients develop
(eg, waking up, going up and down stairs, or exercising).11 In
fact, the UK guidelines consider patients with stuttering priapism
as a group with no obvious underlying risk factors who often
present with self-limiting SRPEs; in other words, with erections
lasting shorter than 1 hour. In contrast to the European guide-
lines, the UK guidelines do not conﬁrm that stuttering priapism
requires a period of erection of at least 4 hours.
Our results show a couple of differences between stuttering
priapism and SRPEs. None of the patients with SRPE had a
hematologic disease, which is the most common cause of stut-
tering priapism. Moreover, the duration of the last nocturnalerection in patients with stuttering priapism often persists for 3
to 4 hours and in one third of all cases ends with ischemic
priapism requiring emergency intervention.6 In contrast, the
duration of SRPEs after awakening is often shorter than 1 hour
and even shorter than 15 minutes in a large number of patients.
Moreover, none of the patients with SRPE needed intervention
other than cooling, micturition, walking around, or simply
“thinking the erection away.” Although we describe 5 patients
who developed painful nonesex-related erections during day-
time, we could not diagnose stuttering priapism, because these
erections disappeared within 4 hours. Moreover, in SRPE, there
is complete erection; in stuttering priapism, the erection is
limited to the cavernous bodies.
This study concerned a retrospective analysis of a limited
population. For this reason, the results were mostly descriptively
assessed. Furthermore, it was not possible to compare the effect
of all treatment forms applied in our patient population, several
drugs had already been applied before they visited our outpatient
clinic, and the groups were too small. The interpretation of
treatment results was strongly dependent on the patients’ sub-
jective perceptions.
However, compared with previous studies, the systematic
overview of symptomatology and impact of this parasomnia on
daily life concerned a relatively large number of patients. In
addition, this study provides a direction for future research,
especially on the role of the pelvic ﬂoor muscles.
CONCLUSIONS
SPRE is a poorly recognized parasomnia that is difﬁcult to
objectify and has debilitating consequences for daily life. How-
ever, sex life is not impaired in most patients. Although the
etiology and pathophysiology of SRPEs have not been clariﬁed,
our results suggest involvement of hypertonic pelvic ﬂoor
muscles. According to our overview of the clinical presentation of
SRPE, we believe that it differs substantially from stuttering
priapism.
Ideally, standard diagnostics would include NPT-R measure-
ment with simultaneous PSG and electromyography, but in
practice this is very difﬁcult to realize. Moreover, it would be
interesting to aspirate blood from the cavernous body during an
SRPE to exclude ischemia.
The results of this study suggest that relief of SRPEs and
consequent improvement of sleep architecture might best be
achieved by baclofen, rather than other treatment modalities.
However, pelvic physiotherapy showed promising results in 3 of
5 patients and its role in the treatment of SRPE needs to be
assessed further.
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